A nomogram‑based immunoprofile predicts clinical outcomes for stage II and III human colorectal cancer
Lingxiong Wang(Chinese PLA General Hospital), Shunchang Jiao(Chinese PLA General Hospital), Zhou Zhou(University of Science and Technology of China), Qiong Wang(Jiangnan University), Jinfeng Li(Hebei Medical University), Liangliang Wu(Beijing Institute of Aeronautical Materials), Jianqing Hao(Qingzhou City People's Hospital), Nijia Chang(Chinese PLA General Hospital), Lijun Zhang(Dalian Medical University), Yin Chen(Chinese PLA General Hospital)
Cited by 23
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer
|Clinical Cancer Research|2014|350
Germline Mutations in Cancer Susceptibility Genes in a Large Series of Unselected Breast Cancer Patients
|Clinical Cancer Research|2017|272